Company: CERO
Filing Date: 2025-11-20
Form Type: 424B3
Source: 0001213900-25-113117
Chunk: 109

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-20
Form: 424B3
Chunk 109
---
 disclosed, we have not been in
compliance with the requirement set forth in Nasdaq Listing Rule 5550(b)(1) to maintain stockholders’ equity of at least $2.5 million
(the “Equity Rule”). In January 2025, a previous Nasdaq panel provided us with an extension until April 22, 2025 to obtain
compliance with the Equity Rule. On April 21, 2025, we announced that, following the completion of a financing round including the issuance
of shares of Series D Preferred Stock in exchange for marketable securities (the “Marketable Securities”) of another public
company convertible under its terms into shares of common stock of such other public company with an aggregate value of $5 million, as
well as the application of the proceeds of our February 2025 public offering of shares of common stock and warrants and the proceeds
of sales under its equity line of credit, as well as successful negotiations with service providers to reduce outstanding balances payable,
we believed that we had regained compliance with the Equity Rule, subject to Nasdaq’s determination, as well as the completion
of valuation procedures. In August 2025, in connection with the finalization of our financial statements for the quarter ended June 30,
2025, as a result of difficulties of completing the valuation of the Marketable Securities in a timely manner, we sold such Marketable
Securities at a substantial discount to the face value thereof and recorded the value of such Marketable Securities at the sale price
thereof. Following the disclosure of such valuation, the Staff informed us of its determination that, as a result of such revised valuation,
we were not in compliance with the Equity Rule.

We have submitted a request
for review of the Staff’s decision by the Nasdaq Listing and Hearing Review Council (the “Council”). We have also commenced
the process of seeking to trade our shares of common stock on the OTC Markets. Currently, we are trading on the OTC Pink Sheets. . However,
we can provide no assurance that the review by the Council will result in the continued listing of our shares of common stock or that
the shares of common stock will be admitted for trading on the OTC Markets. The OTC Markets also are a less liquid market than Nasdaq,
which may have a material adverse effect on the trading price and volume for the common stock. We are also considering listing alternatives,
including applying to list our shares of common stock on another securities exchange.

The delisting of our securities by Nas